HomeCompareLYPHF vs KMB

LYPHF vs KMB: Dividend Comparison 2026

LYPHF yields 529.73% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LYPHF wins by $305.4K in total portfolio value
10 years
LYPHF
LYPHF
● Live price
529.73%
Share price
$0.38
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$351.3K
Annual income
$921.47
Full LYPHF calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — LYPHF vs KMB

📍 LYPHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLYPHFKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LYPHF + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LYPHF pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LYPHF
Annual income on $10K today (after 15% tax)
$45,027.15/yr
After 10yr DRIP, annual income (after tax)
$783.25/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, KMB beats the other by $3,655.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LYPHF + KMB for your $10,000?

LYPHF: 50%KMB: 50%
100% KMB50/50100% LYPHF
Portfolio after 10yr
$198.6K
Annual income
$3,071.91/yr
Blended yield
1.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

LYPHF
No analyst data
Altman Z
1.5
Piotroski
6/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LYPHF buys
0
KMB buys
0
No recent congressional trades found for LYPHF or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLYPHFKMB
Forward yield529.73%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%17%
Portfolio after 10y$351.3K$45.9K
Annual income after 10y$921.47$5,222.34
Total dividends collected$211.1K$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: LYPHF vs KMB ($10,000, DRIP)

YearLYPHF PortfolioLYPHF Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$37,187$26,486.56$11,314$614.45+$25.9KLYPHF
2$85,815$46,025.42$12,867$760.19+$72.9KLYPHF
3$141,454$49,631.95$14,713$945.27+$126.7KLYPHF
4$189,585$38,229.58$16,924$1,181.90+$172.7KLYPHF
5$226,799$23,942.82$19,596$1,486.64+$207.2KLYPHF
6$256,060$13,384.38$22,850$1,882.16+$233.2KLYPHF
7$281,045$7,061.29$26,849$2,399.80+$254.2KLYPHF
8$304,340$3,621.64$31,812$3,083.36+$272.5KLYPHF
9$327,476$1,832.63$38,033$3,994.72+$289.4KLYPHF
10$351,321$921.47$45,918$5,222.34+$305.4KLYPHF

LYPHF vs KMB: Complete Analysis 2026

LYPHFStock

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.

Full LYPHF Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this LYPHF vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LYPHF vs SCHDLYPHF vs JEPILYPHF vs OLYPHF vs KOLYPHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.